Your Good Partner in Biology Research

CCR8

CCR8:Tregs细胞的特异性靶点,催生下一代重磅肿瘤免疫药物!

CCR8在肿瘤浸润的调节性T细胞(Treg)上特异性表达,在辅助型T细胞2(Th2)和肿瘤细胞也均有表达;然而在外周血Treg或正常组织上基本不表达。CCR8的主要作用是参与Tregs和Th2细胞向炎症和肿瘤部位的募集。Tregs增强了肿瘤细胞的浸润能力,通过抑制攻击肿瘤的免疫细胞的免疫反应,从而使肿瘤细胞发生免疫逃逸。研究发现,与正常组织中的Tregs相比,CCR8在人类乳腺癌的肿瘤浸润性Tregs中显著上调,表明CCR8是TME中Tregs上的一个有希望的治疗靶点,而不会引起系统性自身免疫。因此,以CCR8为靶点的抗体,清除肿瘤微环境中的Treg细胞,将改善TME的免疫功能。

CUSABIO-哺乳包膜VLPs平台成功开发CCR8全长膜蛋白(7次跨膜),展示了完整生物活性。

Recombinant Human CCR8-VLPs 活性蛋白实验验证数据

● 经WB验证蛋白特异性

CSB-MP004847HU is detected by Mouse anti-6*His monoclonal antibody.

CSB-MP004847HU is detected by Anti-CCR8 recombinant Antibody

● 功能性ELISA验证高活性

Immobilized human CCR8 at 5 μg/ml can bind Anti-CCR8 recombinant Antibody. The EC50 is 11.13-17.29 ng/mL.

● 经TEM验证蛋白正确组装

The VLP-like structures of CCR8 has been confirmed by TEM.

CCR8 Antibodies

CCR8 for Homo sapiens (Human)

CCR8 Proteins

CCR8 Proteins for Homo sapiens (Human)

CCR8 Proteins for Mus musculus (Mouse)

CCR8 Proteins for Macaca mulatta (Rhesus macaque)